An important dimension of the REALYSA cohort is to be representative of whole population of patients who receive a diagnosis of lymphoma during the same period in France.
The cohort representativeness may for instance be impacted by the types of the centers (CHU, small hospital …) where REALYSA participants are included, compared to all French centers where people diagnosed with lymphoma may be treated. Other difficulties in the care centers, for example to include elderly patients or patients who are very ill, can impact the representativeness of the cohort.
A research project, initiated by Dr. Caroline Le Lan, an intern in the Lyon-Sud Hematology Department, aims to compare the epidemiological, clinical and biological characteristics of patients included in REALYSA in Lyon-Sud with those of patients that would have been eligible but have not been included in REALYSA. This project will thus provide information on the representativeness of REALYSA participants and help identify possible inclusion biases.
This project will use data from patients included in REALYSA between the 1st of November 2018 and 30th of November 2019 at Lyon-Sud. It will also use data from people not included in REALYSA who had a first consultation in Lyon-Sud for their lymphoma diagnosis during the same period.
The first analyses for this project will begin on the 25 July 2022.
For more information about the treatment of your data for this project or in the REALYSA cohort, you can contact the doctor at your treatment centre, or the LYSARC data protection officer at dpo@lysarc.org. You can find more details on your rights regarding your data in the section “Je participe ou j’ai participé à un essai“, or in the Patient Information Leaflet you received at the time of your inclusion in REALYSA.